Intervacc is trading at €0.08, down -14.24%, after a sharp August 12, 2026 decline; no confirmed company-specific catalyst has been identified.
- The latest notable announcement found was the July 30 EMA filing seeking 12-month Strangvac immunity, which does not directly explain today’s decline.
- Broader U.S. markets were broadly stable, offering limited support for a global-market explanation.